News Releases

Home / Investor Relations

 

News Releases

Date Title and Summary
Toggle Summary Tyme Technologies, Inc. Set to Join Russell 3000® Index
NEW YORK , June 25, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced it is set to join the Russell 3000 ®  Index at the conclusion of the Russell U.S.
Toggle Summary Tyme Releases Detailed Data and Analyses with SM-88 From the First Human Study and Compassionate Use Programs
NEW YORK , June 12, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today release detailed patient data and analyses from both the First Human Study (FHS) and Compassionate Use Program of SM-88 in metastatic
Toggle Summary Tyme Appoints Pharma Executive Don DeGolyer to Board of Directors
NEW YORK , May 30, 2018 (GLOBE NEWSWIRE) -- Tyme, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced the appointment of Don DeGolyer to the Company’s board of directors . Mr. DeGolyer is the founder, Chief Executive Officer, and a director of
Toggle Summary Tyme Announces Five Clinical Abstracts at the 2018 ASCO Annual Meeting
NEW YORK , May 17, 2018 (GLOBE NEWSWIRE) -- Tyme , Inc.  (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced the availability of additional clinical data from the Company’s lead candidate SM-88 being presented in five abstracts at the
Toggle Summary Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018
NEW YORK , April 09, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal year ended March 31, 2018 .
Toggle Summary Tyme and JAF Announce Sarcoma Treatment Collaboration
NEW YORK , April 06, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company, today announced that it is collaborating with The Joseph Ahmed Foundation (“JAF”) to provide treatment for metastatic sarcomas. The collaboration will focus on children and young
Toggle Summary Tyme Technologies, Inc. Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
NEW YORK , March 29, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies , Inc.  (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference .  The conference is being held on April 8-10 at the Le
Toggle Summary Tyme Announces First Site Open for its Phase II Trial with SM-88 in Pancreatic Cancer
NEW YORK , March 27, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies , Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that the first site for the Phase II clinical trial evaluating SM-88 therapy for metastatic pancreatic cancer is open and additional clinical sites are scheduled to open
Toggle Summary FDA Acceptance of IND for Tyme to Begin Phase II Trial in Pancreatic Cancer
Initial Clinical Sites Expected to Open Over the Coming Weeks NEW YORK , March 14, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies , Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that the U.S. Food and Drug Administration (“FDA”) has accepted its Investigational New Drug (“IND”)
Toggle Summary Tyme Technologies Announces Closing of Public Offering of Common Stock
Proceeds Allow SM-88 Advancement to Planned Clinical Milestones NEW YORK , March 08, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies , Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that, on March 6, 2018 , it closed its underwritten public offering of 9,000,000 shares of its common stock,